---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-025377"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T21:19:48.064924+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AVROBIO reports positive Phase 1/2 gene therapy data for cystinosis; all patients off oral cysteamine up to 36 months

## Summary
- All six patients remain off oral cysteamine up to 36 months post gene therapy.
- Durable reduction in leukocyte cystine levels; tissue crystals declined below baseline in first 4 patients.
- Neurocognitive tests (Beery VMI) show improvement/stabilization up to 36 months, suggesting CNS impact.
- No drug-related adverse events or serious adverse events reported to date.
- Positive regulatory feedback from FDA and MHRA to align on registration-enabling trial path.

## SEC filing metadata
- accession: 0001140361-23-025377
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000114036123025377/0001140361-23-025377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000114036123025377/brhc20053135_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-025377
- JSON: https://secwatch.observer/filing/0001140361-23-025377.json
- Plain text: https://secwatch.observer/filing/0001140361-23-025377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.